Annexon Inc (ANNX)

$6.48 +0.10 (1.57%)
Market Cap 746.51M
Revenue (ttm) 0.00
Net Income (ttm) -138.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,435,400
Avg Vol 3,011,940
Day's Range N/A - N/A
Shares Out 119.63M
Stochastic %K 26%
Beta 1.19
Analysts Strong Sell
Price Target $14.71

Company Profile

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also devel...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 822 5500
Fax: 650 636 9773
Address:
1400 Sierra Point Parkway, Building C Suite 200, Brisbane, United States
Sowa5000
Sowa5000 Feb. 3 at 11:16 PM
$ANNX Got a solid pipeline. Undervalued adding long calls!
0 · Reply
Lightening_strikes
Lightening_strikes Feb. 1 at 11:44 AM
$ANNX any near term catalysts or all back half 2026.
0 · Reply
Lightening_strikes
Lightening_strikes Jan. 30 at 9:07 PM
$ANNX crushed today
0 · Reply
Consti22
Consti22 Jan. 29 at 9:24 PM
$ANNX
0 · Reply
Lightening_strikes
Lightening_strikes Jan. 28 at 8:51 PM
$ANNX need news for next leg up
0 · Reply
Montu11
Montu11 Jan. 27 at 4:31 PM
$ANNX wake me up when we’re at $15 🫩🥱😴
0 · Reply
Thomas105
Thomas105 Jan. 26 at 8:44 PM
$ANNX nice hammer on the way tomorrow hit 7 again
0 · Reply
makingdoughfromoptions
makingdoughfromoptions Jan. 26 at 8:14 PM
$ANNX $12 calls for Dec paying $2.00 or bit more. Net cost, $4.50-60. IF called, a near triple. If not called, your options expire and your new cost is $4.50. I sold 57 contracts. But my net cost is now $2.75 or so.
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 24 at 2:10 AM
$ANNX Share Price: $6.77 Contract Selected: Jul 17, 2026 $5 Calls Buy Zone: $2.04 – $2.52 Target Zone: $3.60 – $4.40 Potential Upside: 67% ROI Time to Expiration: 174 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
dixiebull
dixiebull Jan. 23 at 3:25 PM
$TE $ANNX $FDMT $BNAI $AA BNAI nhod
0 · Reply
Latest News on ANNX
Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases

Jan 24, 2026, 2:08 AM EST - 10 days ago

Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Jan 16, 2026, 5:05 PM EST - 18 days ago

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon, Inc. (ANNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 5:06 PM EST - 20 days ago

Annexon, Inc. (ANNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026

Jan 12, 2026, 7:00 AM EST - 22 days ago

Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026

Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome

Jan 8, 2026, 8:00 AM EST - 26 days ago

Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome

Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 4:05 PM EST - 27 days ago

Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Dec 16, 2025, 7:31 PM EST - 6 weeks ago

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Annexon: Maintaining "Buy" Rating On Second C1q Inhibitor Advancement For Geographic Atrophy

Nov 20, 2025, 5:23 PM EST - 2 months ago

Annexon: Maintaining "Buy" Rating On Second C1q Inhibitor Advancement For Geographic Atrophy

Annexon Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million

Nov 14, 2025, 4:01 PM EST - 2 months ago

Annexon Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million

Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 12, 2025, 10:55 PM EST - 2 months ago

Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Nov 12, 2025, 4:12 PM EST - 2 months ago

Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Nov 10, 2025, 4:05 PM EST - 3 months ago

Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon, Inc. (ANNX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 7, 2025, 9:58 PM EDT - 5 months ago

Annexon, Inc. (ANNX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Annexon, Inc. (ANNX) Presents at Cantor Global Healthcare Conference 2025 Transcript

Sep 5, 2025, 1:38 AM EDT - 5 months ago

Annexon, Inc. (ANNX) Presents at Cantor Global Healthcare Conference 2025 Transcript

Annexon Biosciences to Participate in Upcoming September Investor Conferences

Aug 27, 2025, 8:00 AM EDT - 5 months ago

Annexon Biosciences to Participate in Upcoming September Investor Conferences

Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Aug 14, 2025, 4:05 PM EDT - 6 months ago

Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

Aug 7, 2025, 4:30 PM EDT - 6 months ago

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

Jul 24, 2025, 7:00 AM EDT - 6 months ago

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

Annexon: Lead GBS Therapy Stokes Near-Term Potential

Jul 14, 2025, 12:47 PM EDT - 7 months ago

Annexon: Lead GBS Therapy Stokes Near-Term Potential

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

Jun 18, 2025, 4:05 PM EDT - 8 months ago

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

May 29, 2025, 4:05 PM EDT - 8 months ago

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

May 19, 2025, 4:05 PM EDT - 9 months ago

Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

May 12, 2025, 8:00 AM EDT - 9 months ago

Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

May 9, 2025, 5:00 PM EDT - 9 months ago

Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress

May 7, 2025, 8:00 AM EDT - 9 months ago

Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress

Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck

Apr 15, 2025, 7:12 AM EDT - 10 months ago

Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

Apr 8, 2025, 4:05 PM EDT - 10 months ago

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

Apr 3, 2025, 6:18 PM EDT - 10 months ago

Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones

Mar 3, 2025, 8:00 AM EST - 1 year ago

Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 4:05 PM EST - 1 year ago

Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference

Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting

Feb 13, 2025, 8:30 AM EST - 1 year ago

Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting

Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 8:00 AM EST - 1 year ago

Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

Dec 16, 2024, 7:30 AM EST - 1 year ago

Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

Nov 14, 2024, 8:00 AM EST - 1 year ago

Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

Annexon Biosciences to Present at the Jefferies London Healthcare Conference

Nov 13, 2024, 4:05 PM EST - 1 year ago

Annexon Biosciences to Present at the Jefferies London Healthcare Conference

Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

Oct 21, 2024, 8:00 PM EDT - 1 year ago

Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

Director William Carson Acquires 3,200 Shares of Annexon Inc (ANNX)

Oct 3, 2024, 1:20 AM EDT - 1 year ago

Director William Carson Acquires 3,200 Shares of Annexon Inc (ANNX)

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Aug 17, 2024, 9:28 AM EDT - 1 year ago

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting

Jul 11, 2024, 6:09 PM EDT - 1 year ago

Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting

Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting

Jun 25, 2024, 5:00 PM EDT - 1 year ago

Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting

Annexon Announces Pricing of $125 Million Underwritten Public Offering

Jun 5, 2024, 11:04 PM EDT - 1 year ago

Annexon Announces Pricing of $125 Million Underwritten Public Offering

Annexon Announces Proposed Public Offering of Common Stock

Jun 4, 2024, 5:06 PM EDT - 1 year ago

Annexon Announces Proposed Public Offering of Common Stock

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Jun 4, 2024, 2:07 PM EDT - 1 year ago

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Annexon's neurological disorder drug meets main goal of late-stage study

Jun 4, 2024, 7:11 AM EDT - 1 year ago

Annexon's neurological disorder drug meets main goal of late-stage study

Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

Jun 3, 2024, 4:30 PM EDT - 1 year ago

Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones

May 13, 2024, 8:00 AM EDT - 1 year ago

Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones

Annexon Biosciences to Present at the Bank of America Health Care Conference

May 9, 2024, 8:00 AM EDT - 1 year ago

Annexon Biosciences to Present at the Bank of America Health Care Conference

Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting

May 7, 2024, 12:30 PM EDT - 1 year ago

Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting

Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting

May 1, 2024, 8:00 AM EDT - 1 year ago

Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting

Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 8:00 AM EDT - 1 year ago

Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

Sowa5000
Sowa5000 Feb. 3 at 11:16 PM
$ANNX Got a solid pipeline. Undervalued adding long calls!
0 · Reply
Lightening_strikes
Lightening_strikes Feb. 1 at 11:44 AM
$ANNX any near term catalysts or all back half 2026.
0 · Reply
Lightening_strikes
Lightening_strikes Jan. 30 at 9:07 PM
$ANNX crushed today
0 · Reply
Consti22
Consti22 Jan. 29 at 9:24 PM
$ANNX
0 · Reply
Lightening_strikes
Lightening_strikes Jan. 28 at 8:51 PM
$ANNX need news for next leg up
0 · Reply
Montu11
Montu11 Jan. 27 at 4:31 PM
$ANNX wake me up when we’re at $15 🫩🥱😴
0 · Reply
Thomas105
Thomas105 Jan. 26 at 8:44 PM
$ANNX nice hammer on the way tomorrow hit 7 again
0 · Reply
makingdoughfromoptions
makingdoughfromoptions Jan. 26 at 8:14 PM
$ANNX $12 calls for Dec paying $2.00 or bit more. Net cost, $4.50-60. IF called, a near triple. If not called, your options expire and your new cost is $4.50. I sold 57 contracts. But my net cost is now $2.75 or so.
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 24 at 2:10 AM
$ANNX Share Price: $6.77 Contract Selected: Jul 17, 2026 $5 Calls Buy Zone: $2.04 – $2.52 Target Zone: $3.60 – $4.40 Potential Upside: 67% ROI Time to Expiration: 174 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
dixiebull
dixiebull Jan. 23 at 3:25 PM
$TE $ANNX $FDMT $BNAI $AA BNAI nhod
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 23 at 6:47 AM
$ANNX RSI: 71.00, MACD: 0.5317 Vol: 0.68, MA20: 5.61, MA50: 4.78 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
1 · Reply
dixiebull
dixiebull Jan. 22 at 10:04 PM
$TE swing got close to 9 again, see if 8.35 holds for amove back to 9 and break to 9.50 $ANNX swing got 7, so see if 6.50 holds for a move to 8 $FDMT ran to break 8, see if 8 can holdnow for 8.50 and 9 $BNAI sideways today but if 8.50 holds then we can get 9 and 9.50 to 10 $AA whiplashy on earnings but if 63.50 can hold it can see 66 to 68
0 · Reply
shitzushimazu
shitzushimazu Jan. 22 at 8:18 PM
$ANNX im in a gain from riding it down from 6 to 2 back to 7
0 · Reply
SMART4TRADER
SMART4TRADER Jan. 22 at 6:39 PM
January 22, 2026 For potential momentum retention $ANNX $SND $SPRU
0 · Reply
Determinedstocks
Determinedstocks Jan. 22 at 2:37 PM
$ANNX
0 · Reply
dixiebull
dixiebull Jan. 22 at 2:37 PM
$ANNX $YOUL $AREC $IRWD $GITS
1 · Reply
dixiebull
dixiebull Jan. 21 at 10:16 PM
$ANNX swing hits 6.90 so if 7 can break we can see 7.50 to 8 $YOUL tagged 2 so I want 1.85 to hold now for 2 break and 2.25 $AREC we caught just at 4 break and it ran to 4.49. see if 4.15 holds for 4.50 break to 5 $IRWD broke 5 so let's see if tha tholds now for 5.50 and 6 to 6.50 $GITS might keep attention tomorrow as well if 1.50 canhold, or dip to 1.35 for a move to 2 and 2.25
0 · Reply
dixiebull
dixiebull Jan. 21 at 9:22 PM
$ANNX hits 2nd target
0 · Reply
garygb
garygb Jan. 21 at 9:15 PM
$ANNX Adding again. Hot stock !
0 · Reply
StockKilla77
StockKilla77 Jan. 21 at 8:54 PM
$ANNX lets gooooooo
0 · Reply
makingdoughfromoptions
makingdoughfromoptions Jan. 21 at 8:51 PM
$ANNX @ BooEmmy: The news is they applied for approval in Europe which has a 93% approval rating for GBS. America will follow this year, sooner than later. Plus, their big gun for Geographic Atrophy had superb results P2 and I think P3 will be similar. The stock is way undervalued for a mid term hold or longer. 2-5 years.
1 · Reply
BooEmmy
BooEmmy Jan. 21 at 8:44 PM
$ANNX Somebody knows something.. news out soon??
0 · Reply